Platelet Activation by a Collagen Analogue in Hemorrhagic Situations (CAPTURE)

University Hospital Center (CHU) Dijon Bourgogne

Status: Completed

Conditions: Platelet Activation; Hemorrhage; Collagen Analog

Treatments: Biological: Blood sampling

Study type: Observational

Funder types: Other

Identifiers

NCT04483245

DE MAISTRE 2019

Details and patient eligibility

About

Dijon University Hospital and the Dijon-based NVH Medicinal Company have developed a recombinant mini-collagen NVH020B with platelet and Willebrand factor binding activity. Its small size and granular, non-fibrillar presentation make it suitable for use as an injectable hemostat in patients with a hemorrhage or other emergency under antiplatelet therapy.

Enrollment: 83 patients

Sex: All

Ages: 18+ years old

Volunteers: Accepts Healthy Volunteers

Inclusion criteria

• • person who has given their non-opposition to inclusion
• adult
• Healthy volunteers or controls (patients seen in consultation, without history of hemmorhage, etc.).

or

• patients with acute bleeding: polytraumatized, or hemorrhage or intracerebral haemorrhage, or bleeding complications at the end surgery (in particular cardiac surgery with ECMO) or
• patients with antiplatelet therapy or
• patients with thrombocytopenia/thrombopathy

Exclusion criteria

• protected adults (curatorship, guardianship)
• person deprived of their liberty by judicial or administrative decision
• pregnant, parturient or breastfeeding woman
• person unable to express their non-opposition
• platelet transfusion on initial management

Trial design

83 participants in 5 patient groups

controls

Description:

persons free of hemorrhage or haemostasis disorder

Treatment:

Biological: Blood sampling

Haemorrhagic

Description:

Acute hemorrhagic patient

Treatment:

Biological: Blood sampling

ECMO

Description:

ECMO surgery patient with hemorrhagic complication

Treatment:

Biological: Blood sampling

polytrauma

Treatment:

Biological: Blood sampling

Platelet disorder

Description:

Patient with an identified platelet disorder or treated with antiplatelet agents

Treatment:

Biological: Blood sampling